[Correspondence] New oral anticoagulants in patients with atrial fibrillation

Christian Ruff and colleagues' meta-analysis reports substantial reductions in stroke and all-cause mortality by use of the new oral anticoagulants (NOACs) compared with warfarin for atrial fibrillation, justifying their increasing use, but also the unequivocal increased risk of gastrointestinal bleeding. Furthermore, the trials included patients with a presumed low risk of gastrointestinal complications and therefore the true risk might be greater outside the clinical trial setting.

Source: LANCET - July 4, 2014 Category: Journals (General) Authors: Michael J R Desborough, Vipul Jairath Tags: Correspondence Source Type: research